Table 2 Seroresponse to Omicron BA.1, BA.5 and Delta

From: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

n-Seroresponse

BNT162b2

SCTV01C

SCTV01E

Omicron BA.1 variant

 Seroresponse rate, n (%)

88 (61.5)

78 (52.0)

106 (76.3)

 95% CIa

53.0, 69.5

43.7, 60.2

68.3, 83.1

 Increase over BNT162b2 (95% CI)b

 

−9.3 (−20.4, 1.8)

14.7 (4.0, 25.5)

 P valueb

 

0.1036

0.0076

 Omicron BA.5 variant

 Seroresponse rate, n (%)

95 (66.4)

69 (46.0)

87 (63.0)

 95% CIa

58.1, 74.1

37.8, 54.3

54.4, 71.1

 Increase over BNT162b2 (95% CI)b

 

−19.6 (−30.5, −8.7)

−4.4 (−15.4, 6.6)

 P valueb

 

0.0006

0.4354

Delta variant

 Seroresponse rate, n (%)

65 (45.5)

52 (34.7)

68 (48.9)

 95% CIa

37.1, 54.0

27.1, 42.9

40.4, 57.5

 Increase over BNT162b2 (95% CI)b

 

−10.5 (−21.9, 0.8)

2.6 (−9.0, 14.2)

 P valueb

 

0.0679

0.6576

  1. Seroresponse for participants with pre-dose <LLOQ is defined as equal to or above LLOQ; seroresponse for participants with pre-dose ≥ LLOQ is defined as ≥4-fold in titers compared to pre-dose titer.
  2. a95% CI of seroresponse rate is based on Clopper-Pearson exact method.
  3. bThe comparison is based on Cochran-Mantel-Haenszel test (CMH) stratified by randomization stratification factors.
Back to article page